Latest Advances in Lung Cancer Research

New treatments for lung cancer, including targeted therapies and immunotherapy, are extending lives and offering hope for patients.

Tagrisso significantly improves survival in patients with unresectable stage III EGFR-mutated lung cancer, offering new hope for a longer life.

Study shows telehealth is as effective as in-person visits for palliative care, maintaining quality of life and survival rates while improving access to care for seriously ill patients.

Lorbrena, a new drug targeting a key protein in cancer cells, shows promise in extending survival for non-small cell lung cancer patients.

Non-smoking Asian American and Pacific Islander women face higher lung cancer risks, prompting research into genetic and environmental causes and new treatments.

“Ground-glass opacity” on lung CT scans, a hazy sign of potential cancer, is linked to higher survival rates, emphasizing the importance of early detection.

The Food and Drug Administration on Thursday approved Amgen’s therapy for patients with the most deadly form of lung cancer.

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

New NCCN guidelines help doctors treat lung cancer more effectively with early detection, personalized treatment plans, and comprehensive supportive care recommendations.

The FDA granted accelerated approval for a new HER2-positive breast cancer treatment, offering hope to patients with advanced cancer after previous treatments have failed.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki, a new drug for treating HER2-positive unresectable or metastatic breast cancer in adults.